Ośrodek Badań Farmaceutycznych I Klinicznych Biofana sp. z o.o.
Research and experimental development on biotechnology
KRS: NIP: REGON:
Overview
Status
Active
Registry date
2003-10-28
Share capital
160,000.00 PLN
Registered address
Przytorze 1, 99-300 Kutno, Poland
Electronic delivery address
AE:PL-63650-34249-ADARW-26
Financials
Revenue history (in k)
Filing timeliness
1 of 6 financial statements was filed late (for 2021, 73 days late). All were audited by a statutory auditor.
- 202506/07/2026
- 202411/07/2025
- 202305/07/2024
- 202204/07/2023
- 202126/09/2022
- 202014/09/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 4.22mMedianUSD 56.72kAverageUSD 2.72m
Net profit
This companyUSD 146.01kMedianUSD -1.27kAverageUSD -93.01k
Operating costs
This companyUSD 2.67mMedianUSD 66.48kAverageUSD 2.68m
Assets
This companyUSD 2.51mMedianUSD 134.71kAverageUSD 3.04m
Industry
Authorized Representatives
Jarosław Kazimierz Walczak age 57 – President
Marek Piotr Wośko age 61 – Attorney-in-fact (sole)
Manner of representation
A member of the management board acting individually.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Agnieszka Katarzyna Erlach age 65 | 40 | $1,800.83 | 4.1667% |
| 105 | $28,363.05 | 65.625% | |
Halina Regina Wośko age 89 | 40 | $7,203.31 | 16.6667% |
Marek Piotr Wośko age 61 | 40 | $1,800.83 | 4.1667% |
Others | 23 | $4,051.86 | 9.3749% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2003-12-01.
40 1600 1462 1016 7910 6000 0005
67 1600 1462 1016 7910 6000 0004
43 2030 0045 1110 0000 0060 3350
Debt
No entries in the National Debtors Register (KRZ).
Public aid
4 public aid cases recorded, with a total value of $355,540.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jan 19, 2023 | Aid for research and development projects: industrial research | $294.3K$294,269 | Prezes Agencji Badań Medycznych | |
| Jan 19, 2023 | Aid for research and development projects: experimental development | $24,743$24,743 | Prezes Agencji Badań Medycznych | |
| Dec 27, 2022 | Aid for research and development projects: industrial research | $36,528$36,528 | Prezes Agencji Badań Medycznych |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Medapp S.A. | $3,351,163.61 | medapp.pl | ||
| Biotechna S.A. | $2,472,888.07 | bsbiotechna.com | ||
| Read-Gene S.A. | $2,163,474.84 | read-gene.com | ||
| Proteon Pharmaceuticals S.A. | $2,026,826.52 | proteonpharmaspolkaakcyjna.pl | ||
| Skinlab P.S.A. | $1,797,229.06 | skinlab.pl | ||
| EIT Rawmaterials Clc East sp. z o.o. | $1,795,803.10 | eitrawmaterials.eu | ||
| RDLS sp. z o.o. | $1,680,515.32 | rdls.pl | ||
| Centrum Badań Weterynaryjnych Vetcomplex sp. z o.o. | $255,522.81 | vetcomplex.pl | ||
| Uvera S.A. | $155,384.29 | uvera.eu | ||
| Luna Laboratory sp. z o.o. | $61,894.23 | lunalab.pl |
Change history
| Date | Event | |
|---|---|---|
| 2022-03-14 | Share capital increase (60,000.00 PLN → 160,000.00 PLN) | |
| 2016-01-22 | PKD change (Removed: 20 codes) | |
| 2010-09-22 | PKD change (Added: 7 codes) | |
| 2010-07-20 | Switch to PKD 2007 (23 PKD 1997 codes → 22 PKD 2007 codes) | |
| 2004-06-04 | Share capital increase (50,000.00 PLN → 60,000.00 PLN) |
FAQ
The main business activity of Ośrodek Badań Farmaceutycznych i Klinicznych Biofana focuses on research and experimental development on biotechnology.
The company was registered in the Polish National Court Register (KRS) on October 28, 2003.
The headquarters is located at: Przytorze 1, 99-300 Kutno.
The share capital of the company is PLN 160,000 (approx. $43,220).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
In 2024, the company generated total revenue of $2,789,701, representing a decrease of 20.2% compared to 2023.
No, in 2024 the company was not profitable, reporting a net loss of $476,962. For comparison, in 2023 the loss was $86,395, meaning the company increased its loss by 424.3%.
The largest operating cost category falls under employee remuneration. This category amounted to $1,427,093 in 2024, representing 48% of all operating expenses.
Last updated: 2026-10-07